Investigational Drug Services, IUHSCC

Indianapolis, Indiana 46202

0 studies enrolling now · 4 studies all time

What they study most

Advanced Solid Tumors, BRAF V600E-mutant Metastatic Colorectal Cancer, Carcinoma, Renal Cell, MSS, RAS-mutant Colorectal Cancer

Studies at this site

• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed
• Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation — Completed
• A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors — Completed
• Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer — Completed